1. < Home

Intravenous immunoglobulin

Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study

Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Clodi E, Levine T, Aggarwal R. Predictors[...]

By sjmartinez • February 8, 2025
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine[...]

By sjmartinez • January 18, 2024
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin

Bae SS, Faure-Kumar E, Ferbas K, Wang J, Shahbazian A, Truong L, Yang H, McMahon M, FitzGerald JD, Charles-Schoeman C. Assessment of antibody levels to[...]

By sjmartinez • June 28, 2023